Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study.

Hayden KM, Zandi PP, West NA, Tschanz JT, Norton MC, Corcoran C, Breitner JC, Welsh-Bohmer KA; Cache County Study Group.

Arch Neurol. 2009 Nov;66(11):1378-83. doi: 10.1001/archneurol.2009.237.

2.

APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.

Bunce D, Fratiglioni L, Small BJ, Winblad B, Bäckman L.

Neurology. 2004 Sep 14;63(5):816-21.

PMID:
15365129
3.

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.

Arch Neurol. 2005 Jun;62(6):975-80.

PMID:
15956169
4.

Apolipoprotein E ε4 allele interacts with sex and cognitive status to influence all-cause and cause-specific mortality in U.S. older adults.

Beydoun MA, Beydoun HA, Kaufman JS, An Y, Resnick SM, O'Brien R, Ferrucci L, Zonderman AB.

J Am Geriatr Soc. 2013 Apr;61(4):525-34. doi: 10.1111/jgs.12156. Epub 2013 Mar 21.

5.

Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.

Kerr DS, Stella F, Radanovic M, Aprahamian I, Bertollucci PH, Forlenza OV.

Bipolar Disord. 2016 Feb;18(1):71-7. doi: 10.1111/bdi.12367. Epub 2016 Feb 15.

PMID:
26877211
6.

Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep.

Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA.

JAMA Neurol. 2013 Dec;70(12):1544-51. doi: 10.1001/jamaneurol.2013.4215.

7.

APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba.

Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A, Unverzagt FW, Hall K, Callahan CM, Saykin AJ, Gureje O, Hake A, Foroud T, Gao S.

Int Psychogeriatr. 2014 Jun;26(6):977-85. doi: 10.1017/S1041610214000167. Epub 2014 Feb 24.

8.

Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.

van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM.

Psychol Med. 2009 Nov;39(11):1907-11. doi: 10.1017/S0033291709005492. Epub 2009 Apr 1.

PMID:
19335933
9.

Association between apolipoprotein E ε4 and longitudinal cognitive decline: nested case-control study among chinese community-dwelling elders.

Ma F, Wang J, Miao R, Zhao W, Wang Q.

Neuropsychobiology. 2011;64(2):102-9. doi: 10.1159/000324991. Epub 2011 Jun 21.

PMID:
21701228
10.

Occupational exposure to pesticides increases the risk of incident AD: the Cache County study.

Hayden KM, Norton MC, Darcey D, Ostbye T, Zandi PP, Breitner JC, Welsh-Bohmer KA; Cache County Study Investigators.

Neurology. 2010 May 11;74(19):1524-30. doi: 10.1212/WNL.0b013e3181dd4423.

11.

Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.

Qiu C, Winblad B, Fratiglioni L.

Neurol Res. 2006 Sep;28(6):650-6.

PMID:
16945218
12.

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.

Arch Neurol. 2007 Sep;64(9):1306-11.

PMID:
17846270
13.

Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.

Yaffe K, Haan M, Byers A, Tangen C, Kuller L.

Neurology. 2000 May 23;54(10):1949-54.

PMID:
10822435
14.

Cognitive resilience to apolipoprotein E ε4: contributing factors in black and white older adults.

Kaup AR, Nettiksimmons J, Harris TB, Sink KM, Satterfield S, Metti AL, Ayonayon HN, Yaffe K; Health, Aging, and Body Composition (Health ABC) Study.

JAMA Neurol. 2015 Mar;72(3):340-8. doi: 10.1001/jamaneurol.2014.3978.

15.

Apolipoprotein E ε4 and later-life decline in cognitive function and grip strength.

Batterham PJ, Bunce D, Cherbuin N, Christensen H.

Am J Geriatr Psychiatry. 2013 Oct;21(10):1010-9. doi: 10.1016/j.jagp.2013.01.035. Epub 2013 Feb 6.

PMID:
23567378
16.

Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study.

Irie F, Masaki KH, Petrovitch H, Abbott RD, Ross GW, Taaffe DR, Launer LJ, White LR.

Arch Gen Psychiatry. 2008 Aug;65(8):906-12. doi: 10.1001/archpsyc.65.8.906.

17.

Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.

Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ.

J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1149-56. doi: 10.1136/jnnp.2010.231555. Epub 2011 Apr 14.

PMID:
21493755
18.

Is ApoE epsilon4 associated with cognitive functioning in African Americans diagnosed with Alzheimer Disease? An exploratory study.

Mount DL, Ashley AV, Lah JJ, Levey AI, Goldstein FC.

South Med J. 2009 Sep;102(9):890-3. doi: 10.1097/SMJ.0b013e3181b21b82.

19.

Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use.

Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL.

PLoS One. 2013;8(2):e54713. doi: 10.1371/journal.pone.0054713. Epub 2013 Feb 13.

20.

Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.

Mielke MM, Leoutsakos JM, Tschanz JT, Green RC, Tripodis Y, Corcoran CD, Norton MC, Lyketsos CG.

J Alzheimers Dis. 2011;26(1):127-34. doi: 10.3233/JAD-2011-110086.

Supplemental Content

Support Center